|
|
Blood, 1 June 2006, Vol. 107, No. 11, pp. 4572-4573.
 Previous Article | Table of Contents
CORRESPONDENCE
To the editor:
Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders
The recent identification of a somatically acquired, gain-of-function mutation in Janus kinase-2, JAK2V617F (Tefferi and Gilliland1 and references therein) in varying proportions of patients with sporadic polycythemia vera (PV) (virtually 100%), idiopathic myelofibrosis (IMF) (50%), and essential thrombocythemia (ET) (25%-50%), raises 2 possibilities with regards to disease pathogenesis: (1) JAK2V617F is sufficient for disease, and the precise phenotype is determined by interindividual differences in genetic background and/or environmental influences; and (2) JAK2V617F is the second mutation in a 2-"hit" model that confers selective growth advantage. Here, the first mutation, which may be genetically heterogeneous and possibly inherited, is also required for disease development.
The study of familial myeloproliferative diseases (MPDs) provides a unique opportunity to distinguish between the above possibilities. Families in which first-degree relatives develop MPDs that are indistinguishable from sporadic MPDs have been previously described, and suggest an autosomal dominant inheritance with incomplete penetrance, particularly for expression of the full disease phenotype.2,3 Notably, a study of 6 families with multiple members with PV revealed clonal hematopoiesis in affected females and erythropoietin-independent erythroid progenitors in healthy family members, thus implicating multiple genetic defects in the early pathogenesis of PV.4 Importantly, in this study, linkage analysis suggested that loss of heterozygosity (LOH) of chromosome 9p (where JAK2 is located) is a secondary change and does not target the primary PV locus. In another pedigree with familial PV, where the 2 affected members were linked by an unaffected obligate carrier, all 3 individuals were found to carry the JAK2V617F mutation, thus favoring the second possibility.5
We studied 2 sibling pairs with familial MPDs for the JAK2V617F mutation (Table 1 and Figure 1) using our recently described allele-specific polymerase chain reaction (AS-PCR) methodology, which is sensitive to 0.01% to 0.1%.6 For each pair, the JAK2V617F mutation was found in the sibling (A11 and B11) with PV-related disease (PV and post-PV myelofibrosis, respectively) and not in the sibling (A12 and B12) with non-PV disease (ET and post-ET myelofibrosis, respectively). Notably, the association between the JAK2V617F mutation and PV held true regardless of whether the disease was early stage (siblings A11 and A12 had asymptomatic disease, and the diagnosis was made incidentally), or advanced stage (siblings B11 and B12 had advanced post-PV and post-ET myelofibrosis, respectively, and were being considered for palliative splenectomy).
Our data supports the hypothesis that the primary locus/loci implicated in familial MPDs remains to be identified, and JAK2V617F may serve as a secondary "patterning" mutation associated with a PV phenotype. Further, as recently shown for an ET cohort,7 acquisition of the JAK2V617F mutation may be independent of disease duration.
View larger version (13K):
[in this window]
[in a new window]
|
Figure 1.. Pedigrees of 2 families with familial MPD. (A) Pedigree of family A. (B) Pedigree of family B. Squares indicate males; circles, females. Filled symbols indicate affected individuals; black dots within symbols, possibly affected individuals; strike through, deceased individuals.
|
|
Animesh Pardanani,
Terra Lasho,
Rebecca McClure,
Martha Lacy, and
Ayalew Tefferi
Correspondence: Animesh Pardanani, Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN, 55905; e-mail: pardanani.animesh{at}mayo.edu.
References
- Tefferi A, Gilliland DG. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle. 2005;4: 1053-1056.[Medline]
[Order article via Infotrieve]
- Perez-Encinas M, Bello JL, Perez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol. 1994;46: 225-229.[Medline]
[Order article via Infotrieve]
- Gilbert HS. Familial myeloproliferative disease. Baillieres Clin Haematol. 1998; 11: 849-858.[CrossRef][Medline]
[Order article via Infotrieve]
- Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102: 3793-3796.[Abstract/Free Full Text]
- Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol. 2005;130: 800-801.[CrossRef][Medline]
[Order article via Infotrieve]
- McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders [letter]. Leukemia. 2006;20: 168-171.[Medline]
[Order article via Infotrieve]
- Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366: 1945-1953.[CrossRef][Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Rumi, F. Passamonti, C. Picone, M. G. Della Porta, C. Pascutto, M. Cazzola, and M. Lazzarino
Disease anticipation in familial myeloproliferative neoplasms
Blood,
September 15, 2008;
112(6):
2587 - 2588.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, L. R. Goldin, S. Y. Kristinsson, E. A. Helgadottir, J. Samuelsson, and M. Bjorkholm
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Blood,
September 15, 2008;
112(6):
2199 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani, B. L. Fridley, T. L. Lasho, D. G. Gilliland, and A. Tefferi
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Blood,
March 1, 2008;
111(5):
2785 - 2789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Teofili, R. Foa, F. Giona, and L. M. Larocca
Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
Haematologica,
February 1, 2008;
93(2):
169 - 172.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Pietra, S. Li, A. Brisci, F. Passamonti, E. Rumi, A. Theocharides, M. Ferrari, H. Gisslinger, R. Kralovics, L. Cremonesi, et al.
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Blood,
February 1, 2008;
111(3):
1686 - 1689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rumi, F. Passamonti, M. G. Della Porta, C. Elena, L. Arcaini, L. Vanelli, C. Del Curto, D. Pietra, E. Boveri, C. Pascutto, et al.
Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation
J. Clin. Oncol.,
December 10, 2007;
25(35):
5630 - 5635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Coronel, G. Berecki, and T. Opthof
Why the Brugada syndrome is not yet a disease: Syndromes, diseases, and genetic causality
Cardiovasc Res,
December 1, 2006;
72(3):
361 - 363.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Pardanani, R. L. Levine, T. Lasho, Y. Pikman, R. A. Mesa, M. Wadleigh, D. P. Steensma, M. A. Elliott, A. P. Wolanskyj, W. J. Hogan, et al.
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Blood,
November 15, 2006;
108(10):
3472 - 3476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
